- cafead Jan 25, 2023 at 11:02: AM
via Despite a down year in M&A in 2022 for life sciences, 2023 is expected to be the beginning of a “new phase of large-scale dealmaking” in biopharma and medical devices, according to the 2023 EY Firepower report.
The report was released at the J.P. Morgan 41st Annual Life Sciences Conference 2023 held in San Francisco earlier this month. “Firepower” in the report is defined by EY as the “capacity to do M&A based on the strength of its balance sheet.”
article source
The report was released at the J.P. Morgan 41st Annual Life Sciences Conference 2023 held in San Francisco earlier this month. “Firepower” in the report is defined by EY as the “capacity to do M&A based on the strength of its balance sheet.”
article source